**Supplementary file 6.** Clinicopathological parameters per survival tree node in advanced-stage platinum-treated high-grade serous ovarian cancer.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Node 1 (TC 166 / 13q12-q14 / Replication & apoptosis) |  | Low (#) | % | High (#) | % |
| Stage | 34 | 9913 | *88**12* | 13320 | *87**13* |
| Age, mean (range) |  | 59 (23-80) | 61 (38-89) |
| Taxol treated | Yes No | 9022 | *80**20* | 12033 | *78**22* |
| Neo-adjuvant | Yes No | 5107 | *4.5**96* | 7146 | *4.6**95* |
| Debulking | OptimalSuboptimal | 4666 | *41**59* | 8667 | *56**44* |
| Series | 1982920565261939899 | 19588 | *17**4.5**79* | 2532492 | *16**21**2.6**60* |
| 1 year survival (95% CI) | 94% (89-98) | 95% (91-98) |
| 3 year survival (95% CI) | 44% (34-55) | 63% (55-72) |
| 5 year survival (95% CI) | 15% (8-29) | 41% (32-52) |
| Median survival | 991 (823-1159) | 1464 (1281-1861) |

A. Clinicopathological parameters for subgroups defined by node 1 (TC 166 / 13q12-q14 / Replication & apoptosis)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Node 2 (TC 121 / Neuronal development) |  | Low (#) | % | High (#) | % |
| Stage | 34 | 7611 | *87**13* | 232 | *92**8* |
| Age, mean (range) |  | 58 (23-80) | 61 (33-80) |
| Taxol treated | Yes No | 7116 | *82**18* | 196 | *76**6* |
| Neo-adjuvant | Yes No | 582 | *5.7**94* | 25 | *100* |
| Debulking | OptimalSuboptimal | 3651 | *41**59* | 1015 | *40**60* |
| Series | 20565261939899 | 15567 | *17**5.7**77* | 421 | *16**84* |
| 1 year survival (95% CI) | 98% (94-100) | 80% (66-97) |
| 3 year survival (95% CI) | 51% (40-64) | 18% (7-48) |
| 5 year survival (95% CI) | 18% (10-34) | 9% (2-49) |
| Median survival (95% CI) | 1112 (988-1312) | 671 (549-854) |

B. Clinicopathological parameters for subgroups defined by node 2 (TC 121 / Neuronal development)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Node 3 (TC 247 / 11q13-q14 / Proliferation & immune response) |  | Low (#) | % | High (#) | % |
| Stage | 34 | 22 | *100* | 5411 | *83**17* |
| Age, mean (range) |  | 55 (35-76) | 59 (23-80) |
| Taxol treated | Yes No | 202 | *91**9* | 5114 | *79**22* |
| Neo-adjuvant | Yes No | 121 | *4.5**96* | 461 | *6.2**94* |
| Debulking | OptimalSuboptimal | 1210 | *55**46* | 2441 | *37**63* |
| Series | 20565261939899 | 7114 | *32**4.5**64* | 8453 | *12**6.2**82* |
| 1 year survival (95% CI) | 95% (87-100) | 98% (95-100) |
| 3 year survival (95% CI) | 70% (53-94) | 46% (34-62) |
| 5 year survival (95% CI) | 39% (21-72) | 7% (1-34) |
| Median survival (95% CI) | 1342 (1112-NA) | 1007 (796-1233) |

C. Clinicopathological parameters for subgroups defined by node 3 (TC 247 / 11q13-q14 / Proliferation & immune response)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Node 4 (TC 76 / 9p13-p21 / Replication stress) |  | Low (#) | % | High (#) | % |
| Stage | 34 | 162 | *89**11* | 389 | *81**19* |
| Age, mean (range) |  | 52 (23-70) | 62 (39-80) |
| Taxol treated | Yes No | 171 | *94**5.6* | 3413 | *72**28* |
| Neo-adjuvant | Yes No | 117 | *5.6**94* | 344 | *6.4**94* |
| Debulking | OptimalSuboptimal | 711 | *39**61* | 1730 | *36**64* |
| Series | 20565261939899 | 117 | *5.6**94* | 7436 | *15**8.5**77* |
| 1 year survival (95% CI) | 94% (84-100) | 100% (NA-100) |
| 3 year survival (95% CI) | 58% (37-92) | 41% (28-61) |
| 5 year survival (95% CI) | 29% (7-100) | 4% (2-28) |
| Median survival (95% CI) | 1739 (843-NA) | 937 (793-1159) |

D. Clinicopathological parameters for subgroups defined by node 8 (TC 76 / 9p13-p21 / Replication stress)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Node 5 (TC 247 / 11q13-q14 / Proliferation & immune response) |  | Low (#) | % | High (#) | % |
| Stage | 34 | 2872 | *28**72* | 1241 | *23**77* |
| Age, mean (range) |  | 59 (38-87) | 64 (41-87) |
| Taxol treated | Yes No | 7525 | *75**25* | 458 | *85**15* |
| Neo-adjuvant | Yes No | 694 | *6**94* | 152 | *1.9**98* |
| Debulking | OptimalSuboptimal | 5347 | *53**47* | 3320 | *62**38* |
| Series | 1982920565261939899 | 425467 | *4**25**4**67* | 21725 | *40**13**47* |
| 1 year survival (95% CI) | 96% (92-100) | 92% (85-100) |
| 3 year survival (95% CI) | 70% (61-80) | 50% (37-68) |
| 5 year survival (95% CI) | 50% (39-63) | 21% (11-43) |
| Median survival (95% CI) | 1769 (1454-2227) | 1037 (859-1464) |

E. Clinicopathological parameters for subgroups defined by node 5 (TC 247 / 11q13/q14 / Proliferation & immune response)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Node 6 (TC 166 / 13q12-q14 / Replication & apoptosis) |  | Low (#) | % | High (#) | % |
| Stage | 34 | 183 | *86**14* | 302 | *94**6* |
| Age, mean (range) |  | 60 (47-76) | 66 (41-89) |
| Taxol treated | Yes No | 201 | *95**4.8* | 257 | *78**22* |
| Neo-adjuvant | Yes No | 120 | *4.8**95* | 32 | *100* |
| Debulking | OptimalSuboptimal | 165 | *76**24* | 1715 | *53**47* |
| Series | 19829205659899 | 10110 | *48**4.8**48* | 11615 | *34**19**47* |
| 1 year survival (95% CI) | 100 (NA-100) | 87% (76-100) |
| 3 year survival (95% CI) | 84% (65-100) | 30% (16-54) |
| 5 year survival (95% CI) | 37% (17-81) | 12% (3-41) |
| Median survival (95% CI) | 1373 (1220-NA) | 763 (549-1464) |

F. Clinicopathological parameters for subgroups defined by node 6 (TC 166 / 13q12-q14 / Replication & apoptosis)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Node 7 (TC 250 / ECM interactions) |  | Low (#) | % | High (#) | % |
| Stage | 34 | 6410 | *87**14* | 215 | *81**19* |
| Age, mean (range) |  | 58 (38-87) | 61 (44-78) |
| Taxol treated | Yes No | 5816 | *78**22* | 179 | *65**35* |
| Neo-adjuvant | Yes No | 569 | *6.8**93* | 125 | *3.8**96* |
| Debulking | OptimalSuboptimal | 3737 | *50**50* | 1610 | *62**39* |
| Series | 1982920565261939899 | 419348 | *5.4**26**4.1**65* | 6119 | *23**3.8**73* |
| 1 year survival (95% CI) | 97% (94-100) | 92% (83-100) |
| 3 year survival (95% CI) | 75% (65-87) | 64% (48-86) |
| 5 year survival (95% CI) | 58% (45-73) | 28% (13-63) |
| Median survival (95% CI) | 1983 (1663-2685) | 1159 (970-NA) |

G. Clinicopathological parameters for subgroups defined by node 7 (TC 250 / ECM interactions)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Node 8 (Age) |  | ≤ 58 (#) | % | > 58 (#) | % |
| Stage | 34 | 337 | *83**18* | 313 | *91**8.8* |
| Age, mean (range) |  | 51 (38-58) | 67 (58-87) |
| Taxol treated | Yes No | 3010 | *75**25* | 286 | *82**18* |
| Neo-adjuvant | Yes No | 337 | *7.5**93* | 232 | *5.9**94* |
| Debulking | OptimalSuboptimal | 1525 | *38**63* | 2212 | *65**35* |
| Series | 1982920565261939899 | 113125 | *2.5**33**2.5**63* | 36223 | *8.8**18**5.9**68* |
| 1 year survival (95% CI) | 98% (93-100) | 97% (92-100) |
| 3 year survival (95% CI) | 69% (56-86) | 88% (77-100) |
| 5 year survival (95% CI) | 47% (32-69) | 73% (57-93) |
| Median survival (95% CI) | 1687 (1415-2231) | 3233 (2074-NA) |

H. Clinicopathological parameters for subgroups defined by node 8 (Age)